» Articles » PMID: 22119922

Isolation of Influenza Viruses in MDCK 33016PF Cells and Clearance of Contaminating Respiratory Viruses

Overview
Journal Vaccine
Date 2011 Nov 29
PMID 22119922
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

This paper summarizes results obtained by multiplex PCR screening of human clinical samples for respiratory viruses and corresponding data obtained after passaging of virus-positive samples in MDCK 33016PF cells. Using the ResPlexII v2.0 (Qiagen) multiplex PCR, 393 positive results were obtained in 468 clinical samples collected during an influenza season in Germany. The overall distribution of positive results was influenza A 42.0%, influenza B 38.7%, adenovirus 1.5%, bocavirus 0.5%, coronavirus 3.3%, enterovirus 5.6%, metapneumovirus 1.0%, parainfluenza virus 0.8%, rhinovirus 4.1%, and respiratory syncytial virus (RSV) 2.5%. Double infections of influenza virus together with another virus were found for adenovirus B and E, bocavirus, coronavirus, enterovirus and for rhinovirus. These other viruses were rapidly lost upon passages in MDCK 33016PF cells and under conditions as applied to influenza virus passaging. Clinical samples, in which no influenza virus but other viruses were found, were also subject to passages in MDCK 33016PF cells. Using lower inoculum dilutions than those normally applied for preparations containing influenza virus (total dilution of the original sample of ∼10(4)), the positive results for the different viruses turned negative already after 2 or 3 passages in MDCK 33016PF cells. These results demonstrate that, under practical conditions as applied to grow influenza viruses, contaminating viruses can be effectively removed by passages in MDCK cells. In combination with their superior isolation efficiency, MDCK cells appear highly suitable to be used as an alternative to embryonated eggs to isolate and propagate influenza vaccine candidate viruses.

Citing Articles

Developments and current challenges in the process of cell culture-based seasonal influenza vaccine manufacture in Japan.

Hamamoto I Glob Health Med. 2024; 6(2):93-100.

PMID: 38690131 PMC: 11043132. DOI: 10.35772/ghm.2023.01070.


Enhanced isolation of influenza viruses in qualified cells improves the probability of well-matched vaccines.

Peck H, Laurie K, Rockman S, Leung V, Lau H, Soppe S NPJ Vaccines. 2021; 6(1):149.

PMID: 34887440 PMC: 8660794. DOI: 10.1038/s41541-021-00415-3.


Decontamination of surgical face masks and N95 respirators by dry heat pasteurization for one hour at 70°C.

Xiang Y, Song Q, Gu W Am J Infect Control. 2020; 48(8):880-882.

PMID: 32479844 PMC: 7260521. DOI: 10.1016/j.ajic.2020.05.026.


Comparison of suspension MDCK cells, adherent MDCK cells, and LLC-MK2 cells for selective isolation of influenza viruses to be used as vaccine seeds.

Harada Y, Takahashi H, Trusheim H, Roth B, Mizuta K, Hirata-Saito A Influenza Other Respir Viruses. 2019; 14(2):204-209.

PMID: 31651085 PMC: 7040968. DOI: 10.1111/irv.12694.


Cell culture-derived influenza vaccines in the severe 2017-2018 epidemic season: a step towards improved influenza vaccine effectiveness.

Barr I, Donis R, Katz J, McCauley J, Odagiri T, Trusheim H NPJ Vaccines. 2018; 3:44.

PMID: 30323955 PMC: 6177469. DOI: 10.1038/s41541-018-0079-z.


References
1.
Eggers M, Roth B, Schweiger B, Schmid M, Gregersen J, Enders M . Comparison of the novel ResPlex III assay and existing techniques for the detection and subtyping of influenza virus during the influenza season 2006-2007. Eur J Clin Microbiol Infect Dis. 2011; 31(6):1257-65. PMC: 3346937. DOI: 10.1007/s10096-011-1437-1. View

2.
Frank A, Couch R, Griffis C, Baxter B . Comparison of different tissue cultures for isolation and quantitation of influenza and parainfluenza viruses. J Clin Microbiol. 1979; 10(1):32-6. PMC: 273088. DOI: 10.1128/jcm.10.1.32-36.1979. View

3.
Neske F, Blessing K, Tollmann F, Schubert J, Rethwilm A, Kreth H . Real-time PCR for diagnosis of human bocavirus infections and phylogenetic analysis. J Clin Microbiol. 2007; 45(7):2116-22. PMC: 1932993. DOI: 10.1128/JCM.00027-07. View

4.
Gregersen J . A risk-assessment model to rate the occurrence and relevance of adventitious agents in the production of influenza vaccines. Vaccine. 2008; 26(26):3297-304. PMC: 7115387. DOI: 10.1016/j.vaccine.2008.03.076. View

5.
Manning A, Russell V, Eastick K, Leadbetter G, Hallam N, Templeton K . Epidemiological profile and clinical associations of human bocavirus and other human parvoviruses. J Infect Dis. 2006; 194(9):1283-90. PMC: 7199845. DOI: 10.1086/508219. View